Gilead Sciences, Inc. which can be found using ticker (GILD) have now 25 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $116.00 and $71.00 suggesting an average Analsyt target price of $89.76. Given that the stocks previous close was at $74.69 and the analysts are correct then there would likely be a percentage uptick in value of 20.2%. Also worth taking note is the 50 day moving average now sits at $76.73 and the 200 day MA is $78.68. The company has a market capitalization of 94.33B. The stock price for the company is currently $75.70 USD
The potential market cap would be $113,356,974,457 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 16.21, revenue per share of $21.90 and a 9.21% return on assets.
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy, Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV) (Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company’s other products include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases.
